Mostrar el registro sencillo del ítem

dc.contributor.authorGonzalez-Fernandez, Nuria 
dc.contributor.authorMcKee, Krisha
dc.contributor.authorLynch, Rebecca M
dc.contributor.authorGeorgiev, Ivelin S
dc.contributor.authorJimenez, Laura
dc.contributor.authorGrau, Eulalia
dc.contributor.authorYuste-Herranz, Maria Eloisa
dc.contributor.authorKwong, Peter D
dc.contributor.authorMascola, John R
dc.contributor.authorAlcamí, José 
dc.date.accessioned2018-12-17T14:23:22Z
dc.date.available2018-12-17T14:23:22Z
dc.date.issued2018-03-20
dc.identifier.citationPLoS One. 2018 Mar 20;13(3):e0193773.es_ES
dc.identifier.issn1932-6203es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6879
dc.description.abstractBACKGROUND: Only a small fraction of HIV-1-infected patients develop broadly neutralizing antibodies (bNAbs), a process generally associated to chronic antigen stimulation. It has been described that rare aviremic HIV-1-infected patients can generate bNAbs but this issue remains controversial. To address this matter we have assessed bNAb responses in a large cohort of long-term non-progressors (LTNPs) with low or undetectable viremia. METHODS: Samples from the LTNP cohort of the Spanish AIDS Research Network (87 elite and 42 viremic controllers) and a control population of 176 viremic typical-progressors (TPs) were screened for bNAbs using Env-recombinant viruses. bNAb specificities were studied by ELISA using mutated gp120, neutralization assays with mutated viruses, and peptide competition. Epitope specificities were also elucidated from the serum pattern of neutralization against a panel of diverse HIV-1 isolates. RESULTS: Broadly neutralizing sera were found among 9.3% LTNPs, both elite (7%) and viremic controllers (14%). Within the broadly neutralizing sera, CD4 binding site antibodies were detected by ELISA in 4/12 LTNPs (33%), and 16/33 of TPs (48%). Anti-MPER antibodies were detected in 6/12 LTNPs (50%) and 14/33 TPs (42%) whereas glycan-dependent HIV-1 bNAbs were more frequent in LTNPs (11/12, 92%) as compared to TPs (12/33, 36%). A good concordance between standard serum mapping and neutralization-based mapping was observed. CONCLUSION: LTNPs, both viremic and elite controllers, showed broad humoral immune responses against HIV-1, including activity against many major epitopes involved in bNAbs-mediated protection.es_ES
dc.description.sponsorshipThis work was supported by the Spanish AIDS Research Network RD16CIII/0002/0001 that is included in the Spanish I+D+I Plan and is co-financed by ISCIII-Subdirección General de Evaluacion and European Funding for Regional Development (FEDER); Fundación para la investigación y prevención del SIDA en España (FIPSE); Spanish Ministry of Economy and Competitiveness FIS PI16CIII/0034 and intramural research program of the Vaccine Research Centre, National Institute of Allergy and Infectious Diseases. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 681137.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAntibodies, Neutralizing es_ES
dc.subject.meshCD4 Antigens es_ES
dc.subject.meshCohort Studies es_ES
dc.subject.meshDisease Progression es_ES
dc.subject.meshDisease Resistance es_ES
dc.subject.meshEnzyme-Linked Immunosorbent Assay es_ES
dc.subject.meshEpitope Mapping es_ES
dc.subject.meshHEK293 Cells es_ES
dc.subject.meshHIV Antibodies es_ES
dc.subject.meshHIV Infections es_ES
dc.subject.meshHIV-1 es_ES
dc.subject.meshHumans es_ES
dc.subject.meshNeutralization Tests es_ES
dc.subject.meshPolysaccharides es_ES
dc.subject.meshSpain es_ES
dc.subject.meshHIV Long-Term Survivors es_ES
dc.titleCharacterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressorses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29558468es_ES
dc.format.volume13es_ES
dc.format.number3es_ES
dc.format.pagee0193773es_ES
dc.identifier.doi10.1371/journal.pone.0193773es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderEuropean Regional Development Fund 
dc.contributor.funderFundación para la Investigación y la Prevención del Sida en España 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1932-6203es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0193773es_ES
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16CIII/0034es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/681137es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional